Abstract
Corrigendum to An update on the efficacy and safety of aclidinium bromide in patients with COPD by Khuder Alagha, Arnaud Bourdin, Celine Tummino and Pascal Chanez, Therapeutic Advances in Respiratory Disease 2010; Epub ahead of print; [
The authors would like to note an error in the text with respect to a reference on page 7.
‘…The pharmacokinetics and pharmacodynamics of aclidinium have been investigated in a phase I study (doses of 50, 300, and 600 mg) [Donald et al. 2008; Schelfhout et al. 2007]…’
The correct reference should be:
‘…The pharmacokinetics and pharmacodynamics of aclidinium have been investigated in a phase I study (doses of 50, 300, and 600 mg) [Schelfhout et al. 2007]…’
The authors apologise for this error and any confusion it may have caused.